Monobasic sodium phosphate + Dibasic sodium phosphate


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Mild osmotic laxative for bowel evacuation and cleansing
Adult: Available preparation:
Each 45 mL soln contains monobasic sodium phosphate 24.4 g and dibasic sodium phosphate 10.8 g.
45 mL soln diluted in 120 mL cold water for 2 doses 12 hr apart. Each dose should be taken w/ 250 mL of water. For morning appointment, doses are given at 7am then at 7pm on day before procedure. For afternoon appointment, give 1st dose at 7pm on the night before procedure then at 7am on day of procedure.

Oral
Mild osmotic laxative for bowel evacuation and cleansing
Adult: Available preparation:
Each tab contains monobasic sodium phosphate 1.102 g and dibasic sodium phosphate 0.398 g.
4 tab taken w/ 250 mL of clear liq, every 15 min for 5 doses the night before the procedure. Then, 4 tab taken w/ 250 mL of clear liq, every 15 min for 3 doses, 3-5 hr before the procedure.

Rectal
Constipation, Mild osmotic laxative for bowel evacuation and cleansing
Adult: Available preparations:
Each 118 mL enema bottle contains monobasic sodium phosphate 21.4 g and dibasic sodium phosphate 9.4 g.
Each 118 mL enema bottle contains monobasic sodium phosphate 19 g and dibasic sodium phosphate 7 g.
1 bottle once daily.
Child: 3-<12 yr ½ bottle once daily; >12 yr Same as adult dose.
Renal Impairment
Severe: Contraindicated.
Chống chỉ định
Hypercalcaemia, acute phosphate nephropathy (biopsy proven), CHF, ascites, GI obstruction, decreased bowel motility, inflammatory bowel disease (e.g. severe active ulcerative colitis), paralytic ileus, anorectal stenosis, imperforate anus, toxic megacolon, toxic colitis, Hirschsprung’s disease, appendicitis, intestinal perforation, rectal bleeding, dehydration, gastric bypass or stapling surgery. Severe renal impairment.
Thận trọng
Patient w/ CV disorder (e.g. heart failure, HTN, heart disease, acute MI, unstable angina, cardiomyopathy, arrhythmias); rectal ulcers/fissures, colostomy; pre-existing electrolyte imbalance, hypovolaemia, severe chronic constipation, gastric retention, impaired gag reflex; history and risk of seizures. Mild to moderate renal impairment. Elderly or debilitated patients, childn. Pregnancy and lactation.
Phản ứng phụ
Significant: Electrolyte disorders (e.g. hypernatraemia, hyperphosphataemia, hypophosphataemia, hypokalaemia, hypocalcaemia), dehydration, QT prolongation, seizures, fluid loss, hypovolaemia.
Nervous: Dizziness, headache, asthenia.
CV: Oedema.
GI: Nausea, vomiting, diarrhoea, abdominal pain/distention, bloating (oral); rectal bleeding, irritation, pain, stinging.
Resp: Chest pain.
Others: Chills.
Potentially Fatal: Rarely, acute phosphate nephropathy, nephrocalcinosis, severe electrolyte disorders (oral).
Thông tin tư vấn bệnh nhân
Drink sufficient liq before, during and after therapy. This drug may cause dizziness due to dehydration, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor electrolyte balance and renal function, ECG prior and during therapy.
Quá liều
Symptoms: Dehydration, hypotension, tachycardia, bradycardia, tachypnoea, cardiac arrest, shock, resp failure, dyspnoea, paralytic ileus, anxiety, pain, hypernatraemia, hyperphosphataemia, hypokalaemia, hypocalcaemia, acidosis. Management: Symptomatic treatment. Initiate electrolyte correction and fluid replacement therapy immediately. Admin of Ca gluconate may be necessary.
Tương tác
Reduced absorption w/ Ca, Fe, Mg salts, sucralfate. Increased risk of seizures w/ TCA. Increased risk for hyperphosphataemia w/ vit D. Reduced therapeutic effect w/ lithium. Increased risk of ectopic calcification w/ Ca supplements or Ca-containing antacids. Increased risk of hyperkalaemia w/ K phosphates.
Potentially Fatal: Enhanced nephrotoxicity w/ diuretics, ACE inhibitors, NSAIDs.
Tác dụng
Description: Monobasic sodium phosphate and dibasic sodium phosphate are osmotic laxatives. They exert osmotic effect in the small intestine by drawing water into the lumen of the gut producing distention and peristalsis and eventually, evacuation of bowel.
Onset: W/in 30 min to 6 hr (oral); w/in 2-5 min (rectal).
Pharmacokinetics:
Absorption: Approx 1-20% is absorbed from GI tract (oral).
Excretion: Via faeces.
Bảo quản
Store below 25°C.
Phân loại MIMS
References
Anon. Saline Laxatives. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 14/09/2017.

Anon. Sodium Phosphates. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/09/2017.

Buckingham R (ed). Phosphate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/09/2017.

Osmoprep Tablet (Salix Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 14/09/2017.

Ready-To-Use Enema (Rugby Laboratories, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 15/09/2017.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Monobasic sodium phosphate + Dibasic sodium phosphate từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Fleet Phospho-Soda
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in